Galderma Group Ag · SIX:GALD
Galderma — H1 2026 Earnings Presentation
23 slides from Galderma's earnings presentation, Jul 23, 2026
Slide 1: Thumbnails Document Outline Attachments
Thumbnails Document Outline Attachments
Slide 2: Document outline
Slide 1: H1 2026 financial results Slide 2: Forward-looking statements Slide 3 Slide 4 Slide 5: Key financial highlights Slide 6: Continued strong growth momentum Slide 7: Injectable Aesthetics Slide 8: Injectable Aesthetics: Neuromodulators portfolio play strength Slide 9: Injectable Aesthetics: Fi
Slide 3: H1 2026 financial results
H1 2026financial results JULY 23, 2026
Slide 4: Forward-looking statements
2 Forward-looking statements CertainstatementsinthisPresentationareforward-lookingstateme lookingstatementsarestatementsthatarenothistoricalfactsandmaybeidentifiedbywordssuchas"plans","targets","aims","believes","expects","a lookingstatementsreflect,atthetime,Galderma'sbeliefs,intentionsandcurrentta
Slide 5: Key financial highlights
4 Performanceupdate1. 5 Key financial highlights+19-21% Net sales growth at constant currencyRais (previously 17-20%), based on strong trajectory, and confirming Core EBITDA margin, with the intent to continue to inv opportunities2026FULL YEAR GUIDANCEH1 2026CORE EBITDA15Record net sales, surpassing
Slide 6: Continued strong growth momentum
growthStrengthenedfinancial profile andsignificant Core EPS growth, driven by strong Core EBITDA and reduced fina EPS12.34USD+68.5%Year-on-year growth 6 Continued strong growth momentumGrowth predominantlydriven b complemented by positive mix effectsH1 20263,1341,7591,374H1 20252,4481,4091,039+24.6%
Slide 7: Injectable Aesthetics: Neuromodulators portfolio play strength
Excellence in Rome for top 100 trainers Temple Contour TTT in the US –good meeting, expe H1 by July 10, Q1 apparently low (-40% TBC)TU on IA with Relfydess and Relfydess only (in expected July 3 • Launches going well -Italy achieved 10 M, Spain/Iberia continue really stro segments incl gynecologists
Slide 8: Injectable Aesthetics: Fillers & Biostimulators further expansion
9Injectable Aesthetics: Fillers & Biostimulators furthe International markets and the U.S.Restylane Shaype approval in Thailand AustraliaRoll-out of new technologyExpansion in new marketsU.S. Restylane new indicationsChina Sculptra ra launchesChinalaunch of the SmartClicksyringe 10 719848H1 2025H1 2
Slide 9: Dermatological Skincare: Capturing global growth opportunities
11 Dermatological Skincare: Capturing global growth o gains from January to May 2026 (pp),top online Dermatological skincare brandsE-commerce 618 year-on-year growth platform46%10%20%0%TMALLJD.COMDouyin618 campaign execution Expanding Big White Jar to faceSerum for sensitive skinInnovation Continued
Slide 10: Slide 10
Slide 11: Slide 11
Slide 12: Slide 12
Slide 13: Therapeutic Dermatology: Nemluvio and Epiduo
Slide 14: Slide 14
Slide 15: Record financial performance in H1 2026
Slide 16: Slide 16
Slide 17: Strong operating cash flow reduced net leverage to 1.2x
Slide 18: Raising 2026 net sales guidance
Slide 19: Slide 19
Slide 20: Slide 20
Slide 21: Appendix
Slide 22: Enter the password to open this PDF file. File name: File size:
Enter the password to open this PDF file. Cancel OK File name: - File size: - Title: -
Slide 23: Subject: Keywords: Creation Date:
Author: - Subject: - Keywords: - Creation Date: - Modification Date: - Creator: - PDF Producer: - PDF Version: - Page Count: - Page Size: - Fast Web View: - Close Preparing document for printing… 0% Cancel Choose File No file chosen